US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
These patches deliver drugs tropically, where they are absorbed by the skin and into the bloodstream. These provide a consistent delivery of small amounts of a drug into the bloodstream over a long period of time. The length of wear time and the amount of drug delivered is different from patch to patch. To date, around 30 transdermal patches have entered the US market which is indicated for the management of wide range of diseases including cardiovascular diseases, neurological disorders, hormonal therapy, and other therapeutic conditions. Apart from this, several others are present in clinical trials, which are expected to enter the market during the forecast period.
As with any drug delivery system, there exists the potential for side effects with transdermal patches also which restrains their growth in market. The most likely side effect of a transdermal patch is irritated skin. Some wearers may have sensitive skin, making them more vulnerable to a reaction. Sensitivity can also result from the drug itself or the dose being too high. Apart from this, the high cost associated with the development of novel drug patch combination is anticipated to limit the investments in transdermal patches.
The US transdermal skin patch market is moderately competitive and the key players are focused on the adoption of various strategies including product innovation, product launches, and approvals. In addition, companies have also adopted collaboration, merger, and acquisitions as their development strategies to sustain the competitive environment in market. For instance, Canoa, a Delaware-based healthcare and pharmaceuticals company, had acquired ProSolus to enhance its position and development of new products in the transdermal space. The rising research and development activities in this field will propel the growth of market.
As per our report findings, the US transdermal patch market is expected to reach US$ 9 Billion by 2028. Increasing demand for painless drug delivery, coupled with ease of self administration of drugs, is anticipated to fuel market growth. The market is also propelled by ongoing technological advancements in the field. Smart patches, for instance, allow auto-injection of medication and help in monitoring various body parameters. They also enable the transmission of patient generated data, thereby improving timing and accuracy of drug administration. Furthermore, collaboration between pharmaceutical companies and drug delivery technology developers and preference for easy to use self administered drug delivery systems will create new market opportunities in coming years.
The report US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028 provides detailed analysis on the approved marketed products along with their price, dosage, and patch availability. The insights into ongoing clinical trials by company, drug class, indication, and phase are also reported. The major players covered in the US transdermal patches market report are AbbVie, Amneal Pharmaceuticals, Cumberland Pharmaceuticals, Glaxosmithkline, Hisamitsu Pharmaceutical and several others. On the basis of indication, the market opportunity is segmented into Alzheimer, Parkinson, Nicotine Replacement Therapy, Insulin, Vaccine, and Cardiovascular Disease.
US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Research Methodology
- US Transdermal Patch Market Opportunity > USD 9 Billion
- Market Availability, Dosage & Price Analysis On FDA Approved Patches
- US Transdermal Patch Market Opportunity Assessment By Indication
- US Transdermal Patch Clinical Pipeline Clinical Insight by Company, Drug Class, Indication & Phase
- Comprehensive Insight On Approved Patches In Clinical Trials: > 40 Patch
- Transdermal Patch Patent Insight
- Insight On Marketed Transdermal Patch: > 30 FDA Approved Patch
These patches deliver drugs tropically, where they are absorbed by the skin and into the bloodstream. These provide a consistent delivery of small amounts of a drug into the bloodstream over a long period of time. The length of wear time and the amount of drug delivered is different from patch to patch. To date, around 30 transdermal patches have entered the US market which is indicated for the management of wide range of diseases including cardiovascular diseases, neurological disorders, hormonal therapy, and other therapeutic conditions. Apart from this, several others are present in clinical trials, which are expected to enter the market during the forecast period.
As with any drug delivery system, there exists the potential for side effects with transdermal patches also which restrains their growth in market. The most likely side effect of a transdermal patch is irritated skin. Some wearers may have sensitive skin, making them more vulnerable to a reaction. Sensitivity can also result from the drug itself or the dose being too high. Apart from this, the high cost associated with the development of novel drug patch combination is anticipated to limit the investments in transdermal patches.
The US transdermal skin patch market is moderately competitive and the key players are focused on the adoption of various strategies including product innovation, product launches, and approvals. In addition, companies have also adopted collaboration, merger, and acquisitions as their development strategies to sustain the competitive environment in market. For instance, Canoa, a Delaware-based healthcare and pharmaceuticals company, had acquired ProSolus to enhance its position and development of new products in the transdermal space. The rising research and development activities in this field will propel the growth of market.
As per our report findings, the US transdermal patch market is expected to reach US$ 9 Billion by 2028. Increasing demand for painless drug delivery, coupled with ease of self administration of drugs, is anticipated to fuel market growth. The market is also propelled by ongoing technological advancements in the field. Smart patches, for instance, allow auto-injection of medication and help in monitoring various body parameters. They also enable the transmission of patient generated data, thereby improving timing and accuracy of drug administration. Furthermore, collaboration between pharmaceutical companies and drug delivery technology developers and preference for easy to use self administered drug delivery systems will create new market opportunities in coming years.
The report US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028 provides detailed analysis on the approved marketed products along with their price, dosage, and patch availability. The insights into ongoing clinical trials by company, drug class, indication, and phase are also reported. The major players covered in the US transdermal patches market report are AbbVie, Amneal Pharmaceuticals, Cumberland Pharmaceuticals, Glaxosmithkline, Hisamitsu Pharmaceutical and several others. On the basis of indication, the market opportunity is segmented into Alzheimer, Parkinson, Nicotine Replacement Therapy, Insulin, Vaccine, and Cardiovascular Disease.
1. RESEARCH METHODOLOGY
2. INTRODUCTION TO TRANSDERMAL PATCH
2.1 Classification of Transdermal Patches
2.2 Why There Exist Need for Transdermal Patches?
2.3 Mechanism of Transdermal Patch Drug Delivery
3. US TRANSDERMAL PATCH MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Patch Market Opportunity Assessment By Indication
3.2.1 Parkinson’s Disease
3.2.2 Alzheimer's Disease
3.2.3 Female Contraceptive
3.2.4 Nicotine Replacement Therapy
3.2.5 Cardiovascular Disease
3.2.6 Insulin
3.2.7 Vaccine
3.3 US Transdermal Patch Market Future Trends
4. US TRANSDERMAL PATCH CLINICAL PIPELINE OVERVIEW
4.1 By Company
4.2 By Drug Class
4.3 By Indication
4.4 By Phase
5. CARDIOVASCULAR DISEASES TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
5.1 Clonidine Transdermal Patch (Catapres–TTS)
5.2 Nitroglycerin Transdermal Patch
6. OPIOID DRUG CONTAINING TRANSDERMAL PATCHES - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
6.1 Fentanyl Transdermal Patch (Duragesic)
6.2 Buprenorphine Transdermal Patch (Butrans Patch)
7. NEUROLOGICAL DISORDERS TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
7.1 Selegiline Transdermal Patch (Emsam)
7.2 Scopolamine Transdermal Patch (Transderm-Scop)
7.3 Rivastigmine Transdermal Patch (Exelon)
7.4 Methylphenidate Transdermal Patch (Daytrana)
7.5 Asenapine Transdermal Patch (Secuado)
7.6 Rotigotine Transdermal Patch (Neupro)
7.7 Donepezil Transdermal Patch (Adlarity)
7.8 Dextroamphetamine Transdermal Patch (Xelstrym)
8. HORMONAL THERAPY TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
8.1 Estradiol Transdermal Patch
8.2 Testosterone Transdermal Patch (Androderm)
8.3 Ethinyl Estradiol & Norelgestromin Transdermal Patch
8.4 Estradiol/Levonorgestrel Transdermal Patch (Climara Pro)
8.5 Ethinyl Estradiol/Levonorgestrel (Twirla)
9. TRANSDERMAL PATCHES FOR OTHER CONDITIONS - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
9.1 Nicotine Transdermal Patch (Nicoderm CQ/Harbitrol)
9.2 Oxybutynin Transdermal Patch (Oxytrol)
9.3 Sancuso (Granisetron)
10. US TRANSDERMAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION AND PHASE
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III
10.7 Preregistration
10.8 Registered
11. US MARKETED TRANSDERMAL PATCH CLINICAL INSIGHT BY COMPANY & INDICATION
12. US TRANSDERMAL PATCH MARKET DYNAMICS
12.1 Favorable Market Parameters
12.2 Commercialization Challenges
13. COMPETITIVE LANDSCAPE
13.1 AbbVie
13.2 Amneal Pharmaceuticals
13.3 Cumberland Pharmaceuticals
13.4 Glaxosmithkline
13.5 Hisamitsu Pharmaceutical
13.6 Lavipharm S.A.
13.7 Luye Pharma Group
13.8 Novartis
13.9 Nutriband
13.10 Pfizer
13.11 UCB
13.12 Viatris
2. INTRODUCTION TO TRANSDERMAL PATCH
2.1 Classification of Transdermal Patches
2.2 Why There Exist Need for Transdermal Patches?
2.3 Mechanism of Transdermal Patch Drug Delivery
3. US TRANSDERMAL PATCH MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Patch Market Opportunity Assessment By Indication
3.2.1 Parkinson’s Disease
3.2.2 Alzheimer's Disease
3.2.3 Female Contraceptive
3.2.4 Nicotine Replacement Therapy
3.2.5 Cardiovascular Disease
3.2.6 Insulin
3.2.7 Vaccine
3.3 US Transdermal Patch Market Future Trends
4. US TRANSDERMAL PATCH CLINICAL PIPELINE OVERVIEW
4.1 By Company
4.2 By Drug Class
4.3 By Indication
4.4 By Phase
5. CARDIOVASCULAR DISEASES TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
5.1 Clonidine Transdermal Patch (Catapres–TTS)
5.2 Nitroglycerin Transdermal Patch
6. OPIOID DRUG CONTAINING TRANSDERMAL PATCHES - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
6.1 Fentanyl Transdermal Patch (Duragesic)
6.2 Buprenorphine Transdermal Patch (Butrans Patch)
7. NEUROLOGICAL DISORDERS TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
7.1 Selegiline Transdermal Patch (Emsam)
7.2 Scopolamine Transdermal Patch (Transderm-Scop)
7.3 Rivastigmine Transdermal Patch (Exelon)
7.4 Methylphenidate Transdermal Patch (Daytrana)
7.5 Asenapine Transdermal Patch (Secuado)
7.6 Rotigotine Transdermal Patch (Neupro)
7.7 Donepezil Transdermal Patch (Adlarity)
7.8 Dextroamphetamine Transdermal Patch (Xelstrym)
8. HORMONAL THERAPY TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
8.1 Estradiol Transdermal Patch
8.2 Testosterone Transdermal Patch (Androderm)
8.3 Ethinyl Estradiol & Norelgestromin Transdermal Patch
8.4 Estradiol/Levonorgestrel Transdermal Patch (Climara Pro)
8.5 Ethinyl Estradiol/Levonorgestrel (Twirla)
9. TRANSDERMAL PATCHES FOR OTHER CONDITIONS - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
9.1 Nicotine Transdermal Patch (Nicoderm CQ/Harbitrol)
9.2 Oxybutynin Transdermal Patch (Oxytrol)
9.3 Sancuso (Granisetron)
10. US TRANSDERMAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION AND PHASE
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III
10.7 Preregistration
10.8 Registered
11. US MARKETED TRANSDERMAL PATCH CLINICAL INSIGHT BY COMPANY & INDICATION
12. US TRANSDERMAL PATCH MARKET DYNAMICS
12.1 Favorable Market Parameters
12.2 Commercialization Challenges
13. COMPETITIVE LANDSCAPE
13.1 AbbVie
13.2 Amneal Pharmaceuticals
13.3 Cumberland Pharmaceuticals
13.4 Glaxosmithkline
13.5 Hisamitsu Pharmaceutical
13.6 Lavipharm S.A.
13.7 Luye Pharma Group
13.8 Novartis
13.9 Nutriband
13.10 Pfizer
13.11 UCB
13.12 Viatris
LIST OF TABLES
Table 2-1: Differences between Active & Passive Transdermal Patches
Table 2-2: Transdermal Patches for Various Disease Indications
Table 3-1: Features Required in Transdermal Patches
Table 3-2: US - Different Transdermal Drug Delivery Systems Available in Market
Table 3-3: US - Estimated Adoption Rates for Parkinson's Disease Transdermal Patches, 2021-2028
Table 3-4: Description of Neupro Patch for Parkinson’s Disease
Table 3-5: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer's Disease, 2021-2028
Table 3-6: Transdermal Patches for Alzheimer’s Disease
Table 3-7: Description of Ortho Evra Contraceptive Patch
Table 3-8: Difference Between Generic & Branded Transdermal Contraceptive Products
Table 3-9: US - Estimated Adoption Rates for Nicotine Transdermal Patches, 2022-2028
Table 3-10: Clonidine Patch - Difference Between Generic & Branded Transdermal Patch
Table 3-11: US - Estimated Adoption Rates for Hypertension Transdermal Patches, 2021-2028
Table 3-12: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2021-2028
Table 3-13: US - Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2021-2028
Table 6-1: Duragesic - Initial Dose Conversion from Other Opioids
Table 6-2: Butrans – Initial Dose Calculation using Previous Opioid (Morphine) Dosage
Table 7-1: Daytrana - Dose Increment Pattern for Treatment of ADHD
Table 2-1: Differences between Active & Passive Transdermal Patches
Table 2-2: Transdermal Patches for Various Disease Indications
Table 3-1: Features Required in Transdermal Patches
Table 3-2: US - Different Transdermal Drug Delivery Systems Available in Market
Table 3-3: US - Estimated Adoption Rates for Parkinson's Disease Transdermal Patches, 2021-2028
Table 3-4: Description of Neupro Patch for Parkinson’s Disease
Table 3-5: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer's Disease, 2021-2028
Table 3-6: Transdermal Patches for Alzheimer’s Disease
Table 3-7: Description of Ortho Evra Contraceptive Patch
Table 3-8: Difference Between Generic & Branded Transdermal Contraceptive Products
Table 3-9: US - Estimated Adoption Rates for Nicotine Transdermal Patches, 2022-2028
Table 3-10: Clonidine Patch - Difference Between Generic & Branded Transdermal Patch
Table 3-11: US - Estimated Adoption Rates for Hypertension Transdermal Patches, 2021-2028
Table 3-12: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2021-2028
Table 3-13: US - Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2021-2028
Table 6-1: Duragesic - Initial Dose Conversion from Other Opioids
Table 6-2: Butrans – Initial Dose Calculation using Previous Opioid (Morphine) Dosage
Table 7-1: Daytrana - Dose Increment Pattern for Treatment of ADHD
LIST OF FIGURES
Figure 2-1: Steps Involved in Transdermal Permeation
Figure 2-2: Ideal Properties of Transdermal Patch
Figure 2-3: Types of Commercially Available Transdermal Patch
Figure 2-4: Properties of Transdermal Therapeutics
Figure 2-5: Components of Transdermal Patch
Figure 2-6: Types of Permeation Enhancers
Figure 2-7: Schematic Representation of Iontophoresis
Figure 2-8: Mechanism of Scopolamine Transdermal Patch
Figure 2-9: Mechanism of Nicotine Transdermal Patch
Figure 2-10: Mechanism of Female Contraceptive Transdermal Patch
Figure 3-1: Advantages of Transdermal Patches
Figure 3-2: Disadvantages of Transdermal Patches
Figure 3-3: US - Major Reasons Behind Growth of Transdermal Patches
Figure 3-4: US - Transdermal Patch Market (US$ Billion), 2021 - 2028
Figure 3-5: Potential Market Segments of Transdermal Drug Delivery Systems
Figure 3-6: US - Susceptibility of Parkinson Disease Among Males and Females
Figure 3-7: US - Estimated Increase in Parkinson’s Disease Incidences
Figure 3-8: US - Estimated Financial Impact of Parkinson’s Disease on Economy (US$ Billion)
Figure 3-9: US - Parkinson’s Disease Incidences, 2021-2028
Figure 3-10: US - Estimated Sales of Neupro Patch (US$ Million), 2020-2026
Figure 3-11: US - Male & Female Suffering from Alzheimer’s Disease (Million), 2021
Figure 3-12: US - Shares of Male & Female Suffering from Alzheimer’s Disease (%), 2021
Figure 3-13: US - Percentage of Elderly People Suffering from Alzheimer’s Disease, 2021
Figure 3-14: US - Estimated Increase in Alzheimer’s Incidences (Million), 2020, 2030, 2040 & 2050
Figure 3-15: US - Estimated Incidences of Alzheimer’s Disease (Million), 2021-2028
Figure 3-16: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
Figure 3-17: Benefits of Female Contraceptive Transdermal Drug Delivery System
Figure 3-18: US - Decrease in Number of Smokers due to Nicotine Patch, 2005, 2013 & 2019
Figure 3-19: US – Prevalence of Smokers by Gender (%), 2019
Figure 3-20: Factors Responsible for Increased Consumption of Nicotine Patches
Figure 3-21: US – Estimated Cases of Adult Hypertension (Million), 2019, 2025 & 2030
Figure 3-22: US - Hypertension Incidences (Million), 2021-2028
Figure 3-23: Rank of US among Different Diabetes Prone Countries
Figure 3-24: US – Estimated Diabetic Population (Million), 2019, 2025, 2030 & 2045
Figure 3-25: US – Undiagnosed & Diagnosed Diabetic Population (Million), 2019
Figure 3-26: US – Undiagnosed & Diagnosed Diabetic Population (%), 2019
Figure 3-27: US – Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 & 2045
Figure 3-28: US – Estimated Diabetic Population (Million), 2021-2028
Figure 3-29: Benefits of Insulin Transdermal Patch
Figure 3-30: Drawback of Insulin Transdermal Patch
Figure 3-31: Benefits of Vaccine Transdermal Patch
Figure 3-32: Drawbacks of Vaccine Transdermal Patch
Figure 3-33: US – Number of HIV Cases (Million), 2012, 2014 & 2018
Figure 3-34: US – Estimated Number of HIV Cases (Million), 2020, 2025 & 2030
Figure 3-35: US - Estimated HIV Incidences, 2021-2028
Figure 4-1: US - Transdermal Patch Pipeline by Company (Numbers), 2022 till 2028
Figure 4-2: US Transdermal Patch Pipeline by Drug Class (Numbers), 2022 till 2028
Figure 4-3: US Transdermal Patch Pipeline by Indication (Numbers), 2022 till 2028
Figure 4-4: US - Transdermal Patch Pipeline by Phase (%),2021 till 2028
Figure 4-5: US Transdermal Patch Pipeline by Phase (Numbers), 2022 till 2028
Figure 5-1: Catapres-TTS – FDA Approval & First Generic Approval Year
Figure 5-2: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US$), September’2022
Figure 5-3: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US$), September’2022
Figure 5-4: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US$), September’2022
Figure 5-5: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US$), September’2022
Figure 5-6: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US$), September’2022
Figure 5-7: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US$), September’2022
Figure 5-8: Catapres-TTS – Recommended Initial & Incremented Dose (mg/Week)
Figure 5-9: Catapres-TTS – Monthly & Annual Treatment Cost using 0.1mg Dose (US$), September’2022
Figure 5-10: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), September’2022
Figure 5-11: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US$), September’2022
Figure 5-12: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.3mg Film (US$), September’2022
Figure 5-13: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US$), September’2022
Figure 5-14: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.6mg Film (US$), September’2022
Figure 5-15: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.8mg Film (US$), September’2022
Figure 5-16: Nitro TD Patch A – Price for 30 Patch supply & Price Per Unit (US$), September’2022
Figure 5-17: Generic Nitroglycerin Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), September’2022
Figure 5-18: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US$), September’2022
Figure 5-19: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US$), September’2022
Figure 5-20: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.6 mg Film (US$), September’2022
Figure 6-1: Duragesic – FDA Approval Year by Dose
Figure 6-2: Duragesic – First Generic Approval Year by Dose
Figure 6-3: Duragesic - Price for 5 Patch Supply of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US$), September’2022
Figure 6-4: Duragesic - Price per Unit of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US$), September’2022
Figure 6-5: Generic Fentanyl Transdermal Patch - Price for 5 Patch Supply of Various Doses (US$), September’2022
Figure 6-6: Generic Fentanyl Transdermal Patch - Price per Unit of Various Doses (US$), September’2022
Figure 6-7: Butrans – FDA Approval Year by Dose
Figure 6-8: Butrans - Price for 4 Patch Supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), September’2022
Figure 6-9: Butrans - Price per Unit of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), September’2022
Figure 6-10: Generic Buprenorphine Transdermal Patch - Price for 4 Patch supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), September’2022
Figure 7-1: Emsam - Price for 30 Patch Supply & Price Per Unit of Various Doses of Emsam Transdermal Patches (US$), September’2022
Figure 7-2: Emsam - Monthly & Annual Treatment Cost of Parkinson’s Disease (US$), September’2022
Figure 7-3: Transderm-Scop – Price for a Supply of 4, 10 & 24 Patches of 1mg Transdermal Film (US$), September’2022
Figure 7-4: Transderm-Scop – Price for a Supply of 4, 10 & 24 Patches of 1.5mg Transdermal Film (US$), September’2022
Figure 7-5: Generic Scopolamine Transdermal Patch – Price for a Supply of 4, 10 & 24 Patches of 1mg Transdermal Film (US$), September’2022
Figure 7-6: Exelon – Price for 30 Transdermal Patch Supply of Exelon (US$), September’2022
Figure 7-7: Generic Rivastigmine Transdermal Patch – Price for a Supply of 30 Patches of Dose 4.6mg, 9.5mg & 13.3 mg (US$), September’2022
Figure 7-8: Exelon – Initial & Maintenance Dose for the Treatment of Parkinson’s Disease
Figure 7-9: Exelon – Monthly & Annual Treatment Cost for Treatment of Parkinson’s Disease (US$), September’2022
Figure 7-10: Daytrana – Patent Issue & Expiration Year
Figure 7-11: Daytrana - Price for 30 Transdermal Patch Supply of All Doses (US$), September’2022
Figure 7-12: Secuado – Patent Issue & Expiration Year
Figure 7-13: Secuado – Price for 30 Transdermal Film & Price Per Unit of Various Dose Regimens (US$), September’2022
Figure 7-14: Secuado – Recommended Initial & Incremented Dose (mg/Day)
Figure 7-15: US – Aderis Pharma’s Neupro Patent Issue & Expiration Year
Figure 7-16: US – UCB’s Neupro Patent Issue & Expiration Year
Figure 7-17: Neupro – Price for Supply of 30 Transdermal Films & Price Per Unit (US$), September’2022
Figure 7-18: Neupro – Initial & Maximum Recommended Dose for Early Stage Parkinson (mg/day)
Figure 7-19: Neupro – Initial & Maximum Recommended Dose for Advanced Stage Parkinson (mg/day
Figure 7-20: Global – Neupro Sales (US$ Million), 2017-2022*
Figure 7-21: US – Neupro Sales (US$ Million), 2017-2022
Figure 7-22: Global – Neupro Sales by Region (US$ Million), 2021
Figure 7-23: Global – Neupro Sales by Region (US$ Million), 2021
Figure 7-24: Adlarity - Price for 4 Transdermal Patch Supply of All Doses (US$), September’2022
Figure 7-25: Adlarity – Recommended Initial & Incremented Dose (mg/day)
Figure 7-26: Xelstrym – Recommended Initial, Incremented and Maximum Doses (mg/day)
Figure 8-1: Vivelle-Dot – FDA Approval & First Generic Approval Year
Figure 8-2: Vivelle-Dot - Price for a Supply of 8 Patches of Dose 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg (US$), September’2022
Figure 8-3: Vivelle-Dot - Price per Unit of 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch (US$), September’2022
Figure 8-4: Recommended Dose for Treatment of vaginal Atrophy, vasomotor Symptoms, & Postmenopausal Osteoporosis (mg/Day Twice a Week)
Figure 8-5: Minivelle – FDA Approval Year by Dose
Figure 8-6: Minivelle – FDA Approval & First Generic Approval Year
Figure 8-7: US – Minivelle Patent Issue & Expiration Year
Figure 8-8: Minnivelle – Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US$), September’2022
Figure 8-9: Minivelle - Recommended Dose by Indication (mg/Day)
Figure 8-10: Climara – FDA Approval Year by Dose
Figure 8-11: Climara – FDA Approval & First Generic Approval Year
Figure 8-12: Climara – Average Price for a Supply of 4 Transdermal Films & Price Per Unit of Various Doses (US$), March’2021
Figure 8-13: Menostar – Price for a Supply of 4 Patches of Dose 14 mcg (US$), September’2022
Figure 8-14: Generic Estradiol Transdermal Patch – Price Per 4 & 8 Films Supply & Price Per Unit of 0.025mg Film (US$), September’2022
Figure 8-15: Generic Estradiol Transdermal Patch – Price for 4 & 8 Films Supply & Price Per Unit of 0.0375mg Film (US$), September’2022
Figure 8-16: Generic Estradiol Transdermal Patch – Price for 4 and 8 Films Supply & Price Per Unit of 0.05mg Film (US$), September’2022
Figure 8-17: Generic Estradiol Transdermal Patch – Price for 4 Supply & Price Per Unit of 0.06mg Film (US$), September’2022
Figure 8-18: Generic Estradiol Transdermal Patch – Price for 4 and 8 Films Supply & Price Per Unit of 0.075mg Film (US$), September’2022
Figure 8-19: Generic Estradiol Transdermal Patch – Price for 4 and 8 Films Supply & Price Per Unit of 0.1mg Film (US$), September’2022
Figure 8-20: Androderm – Price for 60 Films Supply & per Unit Price of 2mg Transdermal Films (US$), September’2022
Figure 8-21: Androderm – Price for 30 patch Supply & per Unit Price of 4mg Transdermal Patch (US$), September’2022
Figure 8-22: Androderm – Recommended Initial & Maintainence Dose fot Treatment of Hypogonadism (mg/day)
Figure 8-23: Ortho Evara – FDA approval & Withdrawal Year
Figure 8-24: Xulane – FDA Approval & First Generic Approval Year
Figure 8-25: Xulane – Price for a Supply of 3 Patches & Price Per Unit of 35mcg-150mcg Transdermal Patch (US$), September’2022
Figure 8-26: Xulane – Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 8-27: CombiPatch – Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US$), September’2022
Figure 8-28: Climara Pro – Price for a Supply of 4 Films & Price Per Unit of Transdermal Film (US$), September’2022
Figure 8-29: US – Twirla Patent Issue & Expiration Year
Figure 8-30: Twirla – Price for a Supply of 3 Patches & Price Per Unit of 30mcg-120mcg Transdermal Patch (US$), September’2022
Figure 8-31: Twirla – Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 9-1: Nicotine Transdermal Patch – FDA Approval Year by Product
Figure 9-2: Nicoderm CQ – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), September’2022
Figure 9-3: Nicoderm CQ – Price per Unit of 7mg, 14mg & 21mg Transdermal Patch (US$), September’2022
Figure 9-4: Harbitrol – Price for a Supply of 28 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), March’2021
Figure 9-5: Generic Nicotine Patch – Price for a Supply of 7 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), September’2022
Figure 9-6: Generic Nicotine Patch – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), September’2022
Figure 9-7: Generic Nicotine Patch – Price for a Supply of 28 Transdermal Patches of Doses 14mg & 21mg (US$), September’2022
Figure 9-8: Nicoderm CQ – Recommended Dose & Treatment Schedule for Patients with Consumption More Than 10 Cigarette/Days (mg/day)
Figure 9-9: Nicoderm CQ – Recommended Dose & Treatment Schedule for Patients with Consumption of Less Than 10 Cigarette/Days (mg/day)
Figure 9-10: Nicoderm CQ – Full Treatment Cost for Patient with Daily Consumption of Less than 10 Cigarettes & More than 10 Cigarettes (US$), March’2021
Figure 9-11: Oxytrol – Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), September’2022
Figure 9-12: Oxytrol For Women – Price of 4 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), September’2022
Figure 9-13: Oxytrol For Women – Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), September’2022
Figure 9-14: Sancuso – Patent Issue & Expiration Year
Figure 12-1: Transdermal Patch Market Favorable Factors
Figure 12-2: Transdermal Patch Market Commercialization Challenges
Figure 2-1: Steps Involved in Transdermal Permeation
Figure 2-2: Ideal Properties of Transdermal Patch
Figure 2-3: Types of Commercially Available Transdermal Patch
Figure 2-4: Properties of Transdermal Therapeutics
Figure 2-5: Components of Transdermal Patch
Figure 2-6: Types of Permeation Enhancers
Figure 2-7: Schematic Representation of Iontophoresis
Figure 2-8: Mechanism of Scopolamine Transdermal Patch
Figure 2-9: Mechanism of Nicotine Transdermal Patch
Figure 2-10: Mechanism of Female Contraceptive Transdermal Patch
Figure 3-1: Advantages of Transdermal Patches
Figure 3-2: Disadvantages of Transdermal Patches
Figure 3-3: US - Major Reasons Behind Growth of Transdermal Patches
Figure 3-4: US - Transdermal Patch Market (US$ Billion), 2021 - 2028
Figure 3-5: Potential Market Segments of Transdermal Drug Delivery Systems
Figure 3-6: US - Susceptibility of Parkinson Disease Among Males and Females
Figure 3-7: US - Estimated Increase in Parkinson’s Disease Incidences
Figure 3-8: US - Estimated Financial Impact of Parkinson’s Disease on Economy (US$ Billion)
Figure 3-9: US - Parkinson’s Disease Incidences, 2021-2028
Figure 3-10: US - Estimated Sales of Neupro Patch (US$ Million), 2020-2026
Figure 3-11: US - Male & Female Suffering from Alzheimer’s Disease (Million), 2021
Figure 3-12: US - Shares of Male & Female Suffering from Alzheimer’s Disease (%), 2021
Figure 3-13: US - Percentage of Elderly People Suffering from Alzheimer’s Disease, 2021
Figure 3-14: US - Estimated Increase in Alzheimer’s Incidences (Million), 2020, 2030, 2040 & 2050
Figure 3-15: US - Estimated Incidences of Alzheimer’s Disease (Million), 2021-2028
Figure 3-16: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
Figure 3-17: Benefits of Female Contraceptive Transdermal Drug Delivery System
Figure 3-18: US - Decrease in Number of Smokers due to Nicotine Patch, 2005, 2013 & 2019
Figure 3-19: US – Prevalence of Smokers by Gender (%), 2019
Figure 3-20: Factors Responsible for Increased Consumption of Nicotine Patches
Figure 3-21: US – Estimated Cases of Adult Hypertension (Million), 2019, 2025 & 2030
Figure 3-22: US - Hypertension Incidences (Million), 2021-2028
Figure 3-23: Rank of US among Different Diabetes Prone Countries
Figure 3-24: US – Estimated Diabetic Population (Million), 2019, 2025, 2030 & 2045
Figure 3-25: US – Undiagnosed & Diagnosed Diabetic Population (Million), 2019
Figure 3-26: US – Undiagnosed & Diagnosed Diabetic Population (%), 2019
Figure 3-27: US – Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 & 2045
Figure 3-28: US – Estimated Diabetic Population (Million), 2021-2028
Figure 3-29: Benefits of Insulin Transdermal Patch
Figure 3-30: Drawback of Insulin Transdermal Patch
Figure 3-31: Benefits of Vaccine Transdermal Patch
Figure 3-32: Drawbacks of Vaccine Transdermal Patch
Figure 3-33: US – Number of HIV Cases (Million), 2012, 2014 & 2018
Figure 3-34: US – Estimated Number of HIV Cases (Million), 2020, 2025 & 2030
Figure 3-35: US - Estimated HIV Incidences, 2021-2028
Figure 4-1: US - Transdermal Patch Pipeline by Company (Numbers), 2022 till 2028
Figure 4-2: US Transdermal Patch Pipeline by Drug Class (Numbers), 2022 till 2028
Figure 4-3: US Transdermal Patch Pipeline by Indication (Numbers), 2022 till 2028
Figure 4-4: US - Transdermal Patch Pipeline by Phase (%),2021 till 2028
Figure 4-5: US Transdermal Patch Pipeline by Phase (Numbers), 2022 till 2028
Figure 5-1: Catapres-TTS – FDA Approval & First Generic Approval Year
Figure 5-2: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US$), September’2022
Figure 5-3: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US$), September’2022
Figure 5-4: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US$), September’2022
Figure 5-5: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US$), September’2022
Figure 5-6: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US$), September’2022
Figure 5-7: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US$), September’2022
Figure 5-8: Catapres-TTS – Recommended Initial & Incremented Dose (mg/Week)
Figure 5-9: Catapres-TTS – Monthly & Annual Treatment Cost using 0.1mg Dose (US$), September’2022
Figure 5-10: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), September’2022
Figure 5-11: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US$), September’2022
Figure 5-12: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.3mg Film (US$), September’2022
Figure 5-13: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US$), September’2022
Figure 5-14: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.6mg Film (US$), September’2022
Figure 5-15: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.8mg Film (US$), September’2022
Figure 5-16: Nitro TD Patch A – Price for 30 Patch supply & Price Per Unit (US$), September’2022
Figure 5-17: Generic Nitroglycerin Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), September’2022
Figure 5-18: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US$), September’2022
Figure 5-19: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US$), September’2022
Figure 5-20: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.6 mg Film (US$), September’2022
Figure 6-1: Duragesic – FDA Approval Year by Dose
Figure 6-2: Duragesic – First Generic Approval Year by Dose
Figure 6-3: Duragesic - Price for 5 Patch Supply of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US$), September’2022
Figure 6-4: Duragesic - Price per Unit of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US$), September’2022
Figure 6-5: Generic Fentanyl Transdermal Patch - Price for 5 Patch Supply of Various Doses (US$), September’2022
Figure 6-6: Generic Fentanyl Transdermal Patch - Price per Unit of Various Doses (US$), September’2022
Figure 6-7: Butrans – FDA Approval Year by Dose
Figure 6-8: Butrans - Price for 4 Patch Supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), September’2022
Figure 6-9: Butrans - Price per Unit of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), September’2022
Figure 6-10: Generic Buprenorphine Transdermal Patch - Price for 4 Patch supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), September’2022
Figure 7-1: Emsam - Price for 30 Patch Supply & Price Per Unit of Various Doses of Emsam Transdermal Patches (US$), September’2022
Figure 7-2: Emsam - Monthly & Annual Treatment Cost of Parkinson’s Disease (US$), September’2022
Figure 7-3: Transderm-Scop – Price for a Supply of 4, 10 & 24 Patches of 1mg Transdermal Film (US$), September’2022
Figure 7-4: Transderm-Scop – Price for a Supply of 4, 10 & 24 Patches of 1.5mg Transdermal Film (US$), September’2022
Figure 7-5: Generic Scopolamine Transdermal Patch – Price for a Supply of 4, 10 & 24 Patches of 1mg Transdermal Film (US$), September’2022
Figure 7-6: Exelon – Price for 30 Transdermal Patch Supply of Exelon (US$), September’2022
Figure 7-7: Generic Rivastigmine Transdermal Patch – Price for a Supply of 30 Patches of Dose 4.6mg, 9.5mg & 13.3 mg (US$), September’2022
Figure 7-8: Exelon – Initial & Maintenance Dose for the Treatment of Parkinson’s Disease
Figure 7-9: Exelon – Monthly & Annual Treatment Cost for Treatment of Parkinson’s Disease (US$), September’2022
Figure 7-10: Daytrana – Patent Issue & Expiration Year
Figure 7-11: Daytrana - Price for 30 Transdermal Patch Supply of All Doses (US$), September’2022
Figure 7-12: Secuado – Patent Issue & Expiration Year
Figure 7-13: Secuado – Price for 30 Transdermal Film & Price Per Unit of Various Dose Regimens (US$), September’2022
Figure 7-14: Secuado – Recommended Initial & Incremented Dose (mg/Day)
Figure 7-15: US – Aderis Pharma’s Neupro Patent Issue & Expiration Year
Figure 7-16: US – UCB’s Neupro Patent Issue & Expiration Year
Figure 7-17: Neupro – Price for Supply of 30 Transdermal Films & Price Per Unit (US$), September’2022
Figure 7-18: Neupro – Initial & Maximum Recommended Dose for Early Stage Parkinson (mg/day)
Figure 7-19: Neupro – Initial & Maximum Recommended Dose for Advanced Stage Parkinson (mg/day
Figure 7-20: Global – Neupro Sales (US$ Million), 2017-2022*
Figure 7-21: US – Neupro Sales (US$ Million), 2017-2022
Figure 7-22: Global – Neupro Sales by Region (US$ Million), 2021
Figure 7-23: Global – Neupro Sales by Region (US$ Million), 2021
Figure 7-24: Adlarity - Price for 4 Transdermal Patch Supply of All Doses (US$), September’2022
Figure 7-25: Adlarity – Recommended Initial & Incremented Dose (mg/day)
Figure 7-26: Xelstrym – Recommended Initial, Incremented and Maximum Doses (mg/day)
Figure 8-1: Vivelle-Dot – FDA Approval & First Generic Approval Year
Figure 8-2: Vivelle-Dot - Price for a Supply of 8 Patches of Dose 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg (US$), September’2022
Figure 8-3: Vivelle-Dot - Price per Unit of 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch (US$), September’2022
Figure 8-4: Recommended Dose for Treatment of vaginal Atrophy, vasomotor Symptoms, & Postmenopausal Osteoporosis (mg/Day Twice a Week)
Figure 8-5: Minivelle – FDA Approval Year by Dose
Figure 8-6: Minivelle – FDA Approval & First Generic Approval Year
Figure 8-7: US – Minivelle Patent Issue & Expiration Year
Figure 8-8: Minnivelle – Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US$), September’2022
Figure 8-9: Minivelle - Recommended Dose by Indication (mg/Day)
Figure 8-10: Climara – FDA Approval Year by Dose
Figure 8-11: Climara – FDA Approval & First Generic Approval Year
Figure 8-12: Climara – Average Price for a Supply of 4 Transdermal Films & Price Per Unit of Various Doses (US$), March’2021
Figure 8-13: Menostar – Price for a Supply of 4 Patches of Dose 14 mcg (US$), September’2022
Figure 8-14: Generic Estradiol Transdermal Patch – Price Per 4 & 8 Films Supply & Price Per Unit of 0.025mg Film (US$), September’2022
Figure 8-15: Generic Estradiol Transdermal Patch – Price for 4 & 8 Films Supply & Price Per Unit of 0.0375mg Film (US$), September’2022
Figure 8-16: Generic Estradiol Transdermal Patch – Price for 4 and 8 Films Supply & Price Per Unit of 0.05mg Film (US$), September’2022
Figure 8-17: Generic Estradiol Transdermal Patch – Price for 4 Supply & Price Per Unit of 0.06mg Film (US$), September’2022
Figure 8-18: Generic Estradiol Transdermal Patch – Price for 4 and 8 Films Supply & Price Per Unit of 0.075mg Film (US$), September’2022
Figure 8-19: Generic Estradiol Transdermal Patch – Price for 4 and 8 Films Supply & Price Per Unit of 0.1mg Film (US$), September’2022
Figure 8-20: Androderm – Price for 60 Films Supply & per Unit Price of 2mg Transdermal Films (US$), September’2022
Figure 8-21: Androderm – Price for 30 patch Supply & per Unit Price of 4mg Transdermal Patch (US$), September’2022
Figure 8-22: Androderm – Recommended Initial & Maintainence Dose fot Treatment of Hypogonadism (mg/day)
Figure 8-23: Ortho Evara – FDA approval & Withdrawal Year
Figure 8-24: Xulane – FDA Approval & First Generic Approval Year
Figure 8-25: Xulane – Price for a Supply of 3 Patches & Price Per Unit of 35mcg-150mcg Transdermal Patch (US$), September’2022
Figure 8-26: Xulane – Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 8-27: CombiPatch – Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US$), September’2022
Figure 8-28: Climara Pro – Price for a Supply of 4 Films & Price Per Unit of Transdermal Film (US$), September’2022
Figure 8-29: US – Twirla Patent Issue & Expiration Year
Figure 8-30: Twirla – Price for a Supply of 3 Patches & Price Per Unit of 30mcg-120mcg Transdermal Patch (US$), September’2022
Figure 8-31: Twirla – Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 9-1: Nicotine Transdermal Patch – FDA Approval Year by Product
Figure 9-2: Nicoderm CQ – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), September’2022
Figure 9-3: Nicoderm CQ – Price per Unit of 7mg, 14mg & 21mg Transdermal Patch (US$), September’2022
Figure 9-4: Harbitrol – Price for a Supply of 28 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), March’2021
Figure 9-5: Generic Nicotine Patch – Price for a Supply of 7 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), September’2022
Figure 9-6: Generic Nicotine Patch – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), September’2022
Figure 9-7: Generic Nicotine Patch – Price for a Supply of 28 Transdermal Patches of Doses 14mg & 21mg (US$), September’2022
Figure 9-8: Nicoderm CQ – Recommended Dose & Treatment Schedule for Patients with Consumption More Than 10 Cigarette/Days (mg/day)
Figure 9-9: Nicoderm CQ – Recommended Dose & Treatment Schedule for Patients with Consumption of Less Than 10 Cigarette/Days (mg/day)
Figure 9-10: Nicoderm CQ – Full Treatment Cost for Patient with Daily Consumption of Less than 10 Cigarettes & More than 10 Cigarettes (US$), March’2021
Figure 9-11: Oxytrol – Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), September’2022
Figure 9-12: Oxytrol For Women – Price of 4 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), September’2022
Figure 9-13: Oxytrol For Women – Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), September’2022
Figure 9-14: Sancuso – Patent Issue & Expiration Year
Figure 12-1: Transdermal Patch Market Favorable Factors
Figure 12-2: Transdermal Patch Market Commercialization Challenges
